Lee Johnson Capital Management LLC Buys New Shares in Amgen Inc. $AMGN

Lee Johnson Capital Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,708 shares of the medical research company’s stock, valued at approximately $601,000.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Norges Bank purchased a new stake in Amgen in the 4th quarter valued at about $2,164,162,000. Capital World Investors lifted its holdings in shares of Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after acquiring an additional 4,302,237 shares during the period. State Street Corp boosted its position in shares of Amgen by 4.4% in the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after acquiring an additional 1,287,310 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Amgen by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after acquiring an additional 1,035,779 shares during the last quarter. Finally, Amundi grew its holdings in Amgen by 41.1% in the fourth quarter. Amundi now owns 3,396,945 shares of the medical research company’s stock valued at $1,111,854,000 after purchasing an additional 988,856 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Performance

Shares of AMGN stock opened at $337.60 on Monday. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29. The firm’s 50 day moving average price is $340.71 and its two-hundred day moving average price is $345.82. The stock has a market cap of $182.21 billion, a price-to-earnings ratio of 23.49, a price-to-earnings-growth ratio of 3.39 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, analysts anticipate that Amgen Inc. will post 22.38 EPS for the current year.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Morgan Stanley increased their price target on shares of Amgen from $332.00 to $340.00 and gave the stock an “equal weight” rating in a research note on Tuesday, June 9th. Argus lowered their price objective on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research note on Wednesday, May 20th. Piper Sandler restated an “overweight” rating on shares of Amgen in a report on Friday, June 12th. Canaccord Genuity Group started coverage on Amgen in a research report on Monday, April 20th. They issued a “hold” rating and a $366.00 target price on the stock. Finally, Guggenheim lowered their price target on Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a research report on Monday, May 4th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $354.42.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.